{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:09:51Z","timestamp":1785305391673,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>A post hoc analysis of two randomized, placebo\u2013controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1\u00a0s (FEV<jats:sub>1<\/jats:sub>) reversibility to \u03b2<jats:sub>2<\/jats:sub>-agonists and treatment outcomes were assessed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Mean baseline FEV<jats:sub>1<\/jats:sub> reversibility was numerically lower among patients with high (\u2265\u2009400\u00a0cells\/\u00b5L) versus low baseline EOS. Reslizumab produced clinically significant improvement in FEV<jats:sub>1<\/jats:sub>, exacerbation rates and patient-reported outcomes after 52\u00a0weeks, including in patients with high EOS and low FEV<jats:sub>1<\/jats:sub> reversibility (\u2264\u200914%) to \u03b2<jats:sub>2<\/jats:sub>-agonists at baseline.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Clinical trial eligibility criteria stipulating minimum FEV<jats:sub>1<\/jats:sub> reversibility to \u03b2<jats:sub>2<\/jats:sub>-agonists of\u2009\u2265\u200912% might exclude patients who would benefit from treatment with anti-IL-5 biologics.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13223-020-00424-2","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T15:02:45Z","timestamp":1587308565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility"],"prefix":"10.1186","volume":"16","author":[{"given":"J. Christian","family":"Virchow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","volume":"164","author":"A ten Brinke","year":"2001","unstructured":"ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164:744\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","volume":"132","author":"M Amelink","year":"2013","unstructured":"Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336\u201341.","journal-title":"J Allergy Clin Immunol."},{"key":"424_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/9780470694923.ch19","volume-title":"Asthma and rhinitis, Chapter 89","author":"JC Virchow","year":"2000","unstructured":"Virchow JC. Intrinsic Asthma. In: Busse WW, Holgate ST, editors. Asthma and rhinitis, Chapter 89. Oxford: Blackwell Science; 2000. p. 1355\u201378."},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF00172846","volume":"172","author":"JC Virchow","year":"1994","unstructured":"Virchow JC, Kroegel C, Walker C, Matthys H. Cellular and immunological markers of allergic and intrinsic bronchial asthma. Lung. 1994;172:313\u201334.","journal-title":"Lung"},{"key":"424_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1067\/mai.2001.119149","volume":"108","author":"PM O\u2019Byrne","year":"2001","unstructured":"O\u2019Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001;108:503\u20138.","journal-title":"J Allergy Clin Immunol."},{"key":"424_CR6","first-page":"CD10834","volume":"9","author":"HA Farne","year":"2017","unstructured":"Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD10834.","journal-title":"Cochrane Database Syst Rev"},{"key":"424_CR7","first-page":"7","volume":"7","author":"GM Walsh","year":"2013","unstructured":"Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics. 2013;7:7\u201311.","journal-title":"Biologics."},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355\u201366.","journal-title":"Lancet Respir Med."},{"key":"424_CR9","unstructured":"CINQAIR (reslizumab) injection. Prescribing information, Teva Respiratory LLC. Frazer, PA. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Accessed 11 Mar 2020."},{"key":"424_CR10","first-page":"4","volume":"51","author":"RJ Hancox","year":"2018","unstructured":"Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51:4.","journal-title":"Eur Respir J"},{"key":"424_CR11","unstructured":"National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. https:\/\/www.nhlbi.nih.gov\/sites\/default\/files\/media\/docs\/asthgdln_1.pdf. Accessed 11 Mar 2020."}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-020-00424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-020-00424-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-020-00424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:31:30Z","timestamp":1618788690000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-020-00424-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/s13223-020-00424-2","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both trials were conducted in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and local regulatory requirements. The relevant health authorities and local ethics committees or institutional review boards approved the study protocols. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JCV has lectured for and received honoraria from Allergopharma, ALK, Asche Chiesi, AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer Ingelheim, Cipla, Essex\/Schering-Plough, GSK, Janssen-Cilag, Laboratorios LETI, Meda Pharmaceuticals, Merck\/MSD, Mundipharma, Novartis, Nycomed\/ALTANA, Pfizer, Regeneron, Revotar Biopharmaceuticals, Sandoz\/Hexal, Sanofi, Stallergenes, Takeda, Teva Pharmaceuticals, UCB\/Schwarz Pharma, Zydus Cadila and possibly others and has participated in advisory boards for Asche Chiesi, Avontec, Boehringer Ingelheim, Essex\/Schering-Plough, GSK, Janssen-Cilag, MSD, Mundipharma, Novartis, the Paul-Ehrlich-Institut, Revotar Biopharmaceuticals, Sandoz\/Hexal, Sanofi, Takeda, TEVA, UCB\/Schwarz Pharma and possibly others and has received grants from the Deutsche Forschungsgemeinschaft, Land Mecklenburg-Vorpommern, GSK, MSD. LH is a former employee of Teva Pharmaceuticals. MG and ED are employees of Teva Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}